Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
The present invention provides compounds acting as an effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders, in particular compounds which induce selectively apoptosis of degenerated cells providing reduced side effects in living organisms. The compounds of the present invention are characterized by a high selectivity towards neoplastic cells. CLL cells show a higher sensitivity towards the compounds than PBMCs opening a therapeutic window. The EC50 for CLL cells is in the lower micromolar range.
Cyanobacteria, bacteria that obtain their energy through photosynthesis, are of considerable interest as bio-factories, organisms that could be harnessed to…
Small magnetic whirls may revolutionize future data storage and information processing if they can be moved rapidly and reliably in small structures. A team of…
Johannes Gutenberg University Mainz (JGU) has been working in partnership with the University of Hildesheim over the past seven years to establish a new…
Im Mittelpunkt von BioSAM stehen lebende Mikroorganismen wie Hefen oder Bakterien mit einzigartigen Eigenschaften, die technisch genutzt werden sollen. So…
The invention reveals a cost effective method for intensity-modulated radiotherapy (IMRT). Using common 3D printer technology a template based on patients tumor shape is generated, which can be used for defining the position of the individual leaves of a multi leave collimator.